FDA Midazolam Shortage Alert: Distributor Compliance Impact

FDA Drug Shortage Alert: Midazolam Hydrochloride Injection (Current)

The FDA maintains an active drug shortage designation for midazolam hydrochloride injection, a Schedule IV controlled substance widely used for procedural sedation, anesthesia induction, and ICU sedation protocols. Wholesale drug distributors holding midazolam inventory face allocation decisions that affect hospital surgical throughput, ambulatory surgery centers, and emergency departments relying on consistent supply for time-sensitive procedures.

Regulatory Context

Under Section 506C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356c), manufacturers must notify the FDA of permanent discontinuances or interruptions in manufacturing that are likely to lead to meaningful disruptions in supply. The FDA publishes shortage data on its Drug Shortages Database to inform the supply chain of products where current or projected national demand exceeds supply. Midazolam hydrochloride injection currently appears on the active shortages list with multiple manufacturers reporting supply constraints.

The Drug Enforcement Administration (DEA) regulates midazolam as a Schedule IV controlled substance under 21 CFR Part 1308.14(c). Wholesale distributors holding DEA registration must maintain perpetual inventory records and comply with order size limitations when allocating constrained supply. The intersection of FDCA shortage protocols and CSA distribution requirements creates heightened compliance obligations during active shortage periods.

Current Shortage Status

As of the FDA's most recent update, midazolam hydrochloride injection remains on shortage across multiple presentations, including 1 mg/mL, 5 mg/mL, and 10 mg vials and prefilled syringes. Multiple manufacturers have reported intermittent supply interruptions attributed to increased demand and manufacturing capacity constraints. The FDA has not provided a projected resolution date, classifying the shortage as ongoing with no immediate supply normalization anticipated.

Available supply is concentrated among a limited number of manufacturers. Fresenius Kabi, Hikma Pharmaceuticals, and West-Ward/Hikma have reported allocation or backorder statuses on various presentations. The FDA has not exercised temporary importation authority or issued compounding guidance for midazolam during this shortage period, leaving the domestic supply chain dependent on existing manufacturer capacity.

Operational Impact on Wholesale Distributors

Wholesale drug distributors managing midazolam inventory must implement allocation protocols to distribute limited supply across hospital systems, ambulatory surgery centers, and emergency medical services. Fair distribution practices under state wholesale drug distributor statutes require documented allocation methodologies when demand exceeds available inventory. Distributors serving high-volume surgical facilities face competing claims on constrained inventory from trauma centers, pediatric hospitals, and outpatient procedural areas.

Cold chain considerations for midazolam are minimal — the product is stable at controlled room temperature (20-25°C) — but distributors must account for shorter inventory cycle times during shortage conditions. Accelerated turnover reduces buffer stock and increases the operational risk of stockouts between manufacturer shipments. Distributors holding NABP VAWD accreditation must verify that allocation decisions do not constitute preferential treatment that would violate accreditation standards requiring non-discriminatory distribution practices.

State boards of pharmacy in multiple jurisdictions have received inquiries regarding distributor obligations during controlled substance shortages. Distributors must balance CSA recordkeeping requirements with allocation transparency — perpetual inventory records must reflect allocation decisions without creating preferential customer tiers that could trigger board scrutiny. Entities serving safety-net hospitals or critical access facilities may face additional state-level expectations to prioritize emergency department and ICU supply over elective procedural volume.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in ColdChainCheck's directory, 1,234 hold active FDA establishment registration — the baseline requirement for distributing prescription drugs including controlled substances. However, only 63 entities hold NABP VAWD accreditation, which requires documented standard operating procedures for allocation during shortage conditions. The average compliance score of 51/100 places most tracked entities in the "Fair" tier, indicating verified licensure and registration but limited verification of higher-order compliance signals like accreditation or clean enforcement history.

During active drug shortages, distributors in the "Good" tier (281 entities, scores 61-80) and "Excellent" tier (28 entities, scores 81-100) typically demonstrate documented allocation methodologies and transparent shortage communication protocols. Entities in the "Fair" tier (919 entities, scores 41-60) may lack formalized allocation procedures, creating operational risk when customer demand exceeds available midazolam inventory. The 73 entities with FDA recalls on record — including 12 entities with controlled substance-related enforcement actions — warrant additional scrutiny during shortage periods when distribution decision-making carries heightened regulatory visibility.

Practical Guidance for QA and Procurement Teams:

• Verify distributor DEA registration status — Use ColdChainCheck's directory search to confirm that current and prospective midazolam suppliers hold active DEA registration for Schedule IV distribution. Entities lacking DEA authorization cannot legally supply controlled substances regardless of FDA registration status.

• Cross-reference allocation communication — Compare distributor-provided shortage communications against FDA's official shortage list. Entities claiming "manufacturer shortage" for products not on FDA's active list may indicate inventory management issues rather than legitimate supply constraints.

• Document due diligence for allocation decisions — If your organization receives allocation priority from a distributor during shortage conditions, document the basis (contract terms, historical volume, facility type). State boards may request allocation justification during routine inspections.

• Monitor for gray market activity — Shortages create incentive for unauthorized distributors to enter the supply chain. Verify that any new midazolam supplier appears in ColdChainCheck with state licensure in your jurisdiction and clean enforcement history.

ColdChainCheck tracks FDA drug shortage alerts as part of ongoing directory enrichment. See the Regulatory Compliance Guides section for coverage of DSCSA requirements, state licensure verification, and wholesale distributor qualification workflows.

Disclaimer: This article presents publicly available regulatory information for informational purposes only. It does not constitute legal, medical, or procurement advice. Verify current shortage status, distributor licensure, and allocation requirements with the FDA, DEA, and relevant state boards of pharmacy before making supply chain decisions.